In adults with VTE who received anticoagulants for ≥3 mo, VTE-PREDICT predicted recurrence and bleeding at up to 5 y

Richard H White

doi:10.7326/J23-0021

In adults with VTE who received anticoagulants for ≥3 mo, VTE-PREDICT predicted recurrence and bleeding at up to 5 y

Ann Intern Med. 2023 May;176(5):JC59. doi: 10.7326/J23-0021. Epub 2023 May 2.

Author

Richard H White¹

Affiliation

¹ University of California, Davis, Sacramento, California, USA (R.H.W.).

PMID: 37126813
DOI: 10.7326/J23-0021

Abstract

de Winter MA, Büller HR, Carrier M, et al; VTE-PREDICT study group. Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J. 2023;44:1231-1244. 36648242.

Publication types

Comment

MeSH terms

Adult
Anticoagulants* / adverse effects
Hemorrhage / chemically induced
Humans
Recurrence
Risk Factors
Secondary Prevention
Venous Thromboembolism* / drug therapy

Substances

Anticoagulants